REGENERON PHARMACEUTICALS

📅 Upcoming

🕒 Recent(90d)

News

• Regeneron to challenge Ipsen as FDA clears bone disease drug
  Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
  biopharma_dive · 17h ago
• STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
  A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort
  stat · 20h ago
• STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
  A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
  stat · 1d ago
• 11 companies hiring in New Jersey
  Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.
  biospace · 1d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 2d ago
• Regeneron ends eye disease study due to antibody's safety profile
  The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…
  biospace · 2d ago
• EyePoint plummets on pivotal data for main drug
  Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
  biopharma_dive · 3d ago
• EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
  EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
  biospace · 3d ago
• Regeneron ends eye disease trial for anti-CD3 antibody following safety review
  Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.
  fiercebiotech · 3d ago
• 7 companies hiring in North Carolina now
  Looking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.
  biospace · 8d ago